NCT07177937View on ClinicalTrials.gov

A Study of DXC014 in Patients With Advanced Solid Tumors.

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 20, 2025

Primary Completion Date

October 20, 2030

Study Completion Date

October 20, 2030

Conditions
Small Cell Lung CancerMelanomaProstate CancerOther Advanced Solid Tumors
Interventions
DRUG

DXC014

Dose Escalation DXC014, Cohort Expansion DXC014

Trial Locations (3)

100034

Peking University First Hospital, Beijing

310022

Zhejiang Cancer Hospital, Hangzhou

410000

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Hangzhou DAC Biotechnology Co., Ltd.

INDUSTRY